UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 110,762 Shares of Becton, Dickinson and Company $BDX

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its holdings in Becton, Dickinson and Company (NYSE:BDX) by 5.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,777,558 shares of the medical instruments supplier’s stock after selling 110,762 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Becton, Dickinson and Company were worth $268,998,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. Imprint Wealth LLC acquired a new stake in Becton, Dickinson and Company during the 3rd quarter valued at $25,000. SHP Wealth Management acquired a new position in shares of Becton, Dickinson and Company in the fourth quarter valued at $26,000. Meeder Asset Management Inc. increased its holdings in shares of Becton, Dickinson and Company by 152.2% in the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 102 shares during the last quarter. Main Street Group LTD bought a new position in shares of Becton, Dickinson and Company in the first quarter valued at about $29,000. Finally, Bell Investment Advisors Inc acquired a new stake in shares of Becton, Dickinson and Company during the 2nd quarter worth about $29,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP Michael Feld sold 165 shares of the firm’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the sale, the executive vice president owned 19,720 shares of the company’s stock, valued at $3,717,022.80. This trade represents a 0.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the sale, the executive vice president owned 14,856 shares in the company, valued at $2,686,559.04. This represents a 14.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 9,105 shares of company stock worth $1,590,208. 0.40% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Wells Fargo & Company lifted their target price on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Piper Sandler raised their price objective on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. The Goldman Sachs Group decreased their target price on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 27th. Royal Bank Of Canada lifted their price target on Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a report on Thursday, August 13th. Finally, Bank of America boosted their price target on Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a “neutral” rating in a research note on Monday. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Hold” and a consensus price target of $187.67.

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $188.13 on Tuesday. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $51.84 billion, a P/E ratio of 56.67, a P/E/G ratio of 13.36 and a beta of 0.19. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $193.07. The firm has a 50-day moving average price of $167.10 and a two-hundred day moving average price of $160.32.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same quarter in the prior year, the business posted $3.68 EPS. The business’s revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be given a $1.05 dividend. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company’s payout ratio is presently 126.51%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.